

Systemic Therapy Education Bulletin

BC Cancer news and updates from across the province for Systemic Therapy teams

Provincial Systemic Therapy Drug Programs Under Consideration



The goal of the Education Bulletin is to support health care staff as they prepare for new treatments and to ensure safe patient care during the administration, distribution and management of new and complex treatments. These new drug treatments may also be delivered to patients prior to formal listing through manufacturer patient support programs or clinical trials. Full details around the funded indications and eligibility criteria will be available in the Protocol Summaries and summarized in the Systemic Therapy Update newsletter once funding decisions have been finalized. More details about the drugs, approved indications, and side effects can be found in the BC Cancer drug monographs, accessible from the Cancer Drug Manual [Drug Index](#).

GOCABR

Treatment Programs	Indication (Refer to protocol for more details)	Associated Adverse Events
Paclitaxel NAB (ABRAXANE) Plus Carboplatin	Alternative Treatment of gynecological malignancies	Possible adverse events: <ul style="list-style-type: none"> • Infusion-related reaction • Anemia • Leukopenia • Neutropenia • Thrombocytopenia • Nausea and vomiting • Diarrhea • Mucositis • Arthralgia/myalgia • Asthenia • Sensory neuropathy • Alopecia

Dosing and Administration Information

Pre-medications:

- **Antiemetic:** moderate emetogenicity (see [SCNAUSEA](#))

Dosing and Schedule: One cycle = 21 to 28 days

- **IV paclitaxel NAB (ABRAXANE)** 260 mg/m² infuse over 30 minutes
 - In empty sterile bag and tubing with 15 micron filter
 Plus
- **IV carboplatin** AUC 6 infuse over 30 minutes
 - If extensive prior radiation therapy, use AUC 5

BC Cancer Assigned Nurse and Chair Time

Cycle	Final Nurse Time (Rounded up to next 5min interval)	Final Chair Time (Rounded up to next 5min interval)
Cycle 1	70	160
Cycle 2+	55	145

GOCABRBEV

Treatment Programs	Indication: Under Review (Refer to protocol for more details)	Associated Adverse Events
Paclitaxel NAB (ABRAXANE) Plus Carboplatin Plus Bevacizumab	Alternative Treatment of gynecological malignancies	Possible adverse events (of any grade): <ul style="list-style-type: none"> • Infusion-related reaction • Anemia • Leukopenia • Neutropenia • Thrombocytopenia • Nausea and vomiting • Diarrhea • Mucositis • Arthralgia/myalgia • Asthenia • Sensory neuropathy • Alopecia • Hypertension • Proteinuria • Poor wound healing

Dosing and Administration Information

Pre-medications:

- **Antiemetic:** moderate emetogenicity (see [SCNAUSEA](#))

Dosing and Schedule: One cycle = 21 days

- **IV paclitaxel NAB (ABRAXANE)** 260 mg/m² infuse over 30 minutes
 - In empty sterile bag and tubing with 15 micron filter
 Plus
- **IV carboplatin** AUC 6 infuse over 30 minutes
 - If extensive prior radiation therapy, use AUC 5
 Plus
- **IV bevacizumab**
 - For ovarian cancer: 7.5 mg/kg infuse over 15 minutes*
 - For cervical cancer: 15 mg/kg infuse over 30 minutes*

* **First Bevacizumab infusion over 60 minutes**

Additional Protocol Information:

- Blood pressure measurement pre-bevacizumab
- Blood pressure measurement post-bevacizumab for the first 3 cycles
- Urine dipstick analysis or laboratory urinalysis for protein should be performed at baseline and then prior to each cycle

BC Cancer Assigned Nurse and Chair Time

Cycle	Final Nurse Time (Rounded up to next 5min interval)	Final Chair Time (Rounded up to next 5min interval)
Cycle 1 (Ovarian Cancer Option)	80	240
Cycle 2+ (Ovarian Cancer Option)	65	170
Cycle 1 (Cervical Cancer Option)	80	240
Cycle 2+ (Cervical Cancer Option)	65	195

Website Resources and Contact Information

CONTACT INFORMATION	EMAIL
To subscribe or update contact information, please contact:	
Provincial Systemic Therapy Program	ProvincialSystemicOffice@bccancer.bc.ca
Systemic Therapy Education Bulletin: http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/education-bulletin	